The Austrian company has established a cGMP manufacturing process for its measles vector technology and built a broad pipeline with both proprietary and partnered infectious disease vaccine candidates. The lead program, in Chikungunya, is soon to enter Phase III development.

In October 2018, Themis bought in additional assets from German research group Max Planck, to expand its immunomodulation platform into oncology.